Can a cancer drug stop a blood disorder before it turns deadly?
NCT ID NCT06802146
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study is for people with high-risk CCUS, a blood condition that can lead to cancer. Participants can choose to be watched or take an oral drug called Inqovi (decitabine/cedazuridine). The goal is to see if early treatment is feasible and safe. The study is small and early, so it won't prove whether the drug works, but it may guide future research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Decitabine and cedazuridine (Inqovi)
What this could lead to
If successful, this could show that early treatment of high-risk CCUS is feasible and safe, potentially preventing progression to blood cancer.
What could go wrong
This is a very early, small pilot study (108 participants) focused on feasibility and safety, not effectiveness. The drug may cause side effects, and it's unknown if early treatment truly prevents cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYTOPENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact